For example, savolitinib is a highly selective small molecule inhibitor which can be used to contrapose advanced GC with mesenchymal epithelial transition factor (MET) abnormalities3,4, but it probably leads to acquired resistance in patients with MET-amplified GC for the target mechanisms of resistance MET D1228V/N/H and Y1230C mutations or high copy number MET gene amplifications5,6. The gene discussed is MET; the disease is gastric cancer.